Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence Authors: Samuel Inshutiyimana, Kush Rajeshbhai Rana, Michael Matiop Aleu, Naomi Bwalya, Bonaventure Nsengimana, Onesmas Kipkurui Published: 2026 ABSTRACT ABSTRACTBackgroundNonadherence to antipsychotics affects nearly half of patients with schizophrenia, leading to rehospitalization, suicidality, and reduced quality of life. Optimizing treatment adherence is critical to prevent disease relapses, which can be life‐threatening. This review provides an updated status of innovative efforts in ensuring treatment adherence and the challenges associated. It also addresses future directions to improve treatment outcomes among patients with schizophrenia.MethodsA narrative review was thoroughly conducted by retrieving peer‐reviewed articles from PubMed, Google Scholar, ScienceDirect, and Web of Science. Articles relevant to the aim of the review and published in English were reviewed and analyzed. A total of 76 articles were included in the final report.ResultsDigital pills have demonstrated adherence detection rates reaching above 95%. Wearable devices such as smart watches collect real‐time behavioral and physiological data such as sleep patterns, heart rate variability, and physical activity that reflect adherence or emerging relapse. These metrics enable clinicians to customize interventions according to the patient adherence profile, allowing shared decision‐making during treatment. Besides, the biomarker‐based monitoring system provides more precise tracking, thus reducing the risk of an unsuitable treatment switch. Aptamer‐based technologies also provide ultrasensitive and noninvasive adherence monitoring through the detection of antipsychotics in body fluids.ConclusionIntegration of wearable and biomarker data enables clinicians to make evidence‐based pharmacological decisions while treating schizophrenic patients. Artificial intelligence promises to facilitate this integration by forecasting medication lapses and suggesting personalized solutions. To fully revolutionize adherence in schizophrenia treatment, pharmacists, psychiatrists, bioengineers, and policymakers should collaborate to address ethical, infrastructural, and financial barriers present in this practice.Keywords: adherence, antipsychotics, artificial intelligence, digital pills, psychiatry, wearable devices Abbreviations brain‐derived neurotrophic factor cerebrospinal fluid electronic health records Food and Drug Administration heart rate variability homovanillic acid interleukin liquid chromatography with tandem mass spectrometry tumor necrosis factor Introduction Schizophrenia is a chronic, disabling mental illness that typically requires long‐term adherence to antipsychotic medications to prevent symptom recurrence. Long‐term antipsychotic treatment reduces hospitalization rates, increases functional recovery, and lowers the chance of relapses [1]. However, nonadherence to antipsychotics affects about 40%–50% of patients with schizophrenia and causes worsening of symptoms, rehospitalization, suicidality, and a much‐reduced quality of life [2]. It often leads to substantial economic burdens, including increased hospitalization costs, more frequent emergency visits, and broader societal costs such as reduced productivity [3]. Relapse episodes usually demand prolonged inpatient care, disrupt psychosocial rehabilitation, and put too much strain on families and healthcare systems [2, 4]. Optimizing adherence to treatment from the start of an illness is critical since recurring relapses are associated with neurological impairment and decreased responsiveness to future treatments [5]. Techniques for monitoring adherence, such as self‐reports, pill counts, and pharmacy refill data, have significant limitations. Pill counts fail to confirm drug intake, whereas self‐reports are subject to social desirability bias and remembering issues. Additionally, pharmacy data lack dose‐timing resolution, making it impractical to detect pill dumping [5, 6]. Consequently, clinicians are often left with incomplete and potentially misleading data, forcing them to make reactive treatment decisions such as irrational increases or switches of medications rather than proactively addressing the root cause of poor patient outcomes [5]. Digital and biomarker‐based solutions are however rapidly emerging to provide continuous, detailed, and objective adherence data [7]. For instance, digital pills, which are ingestible sensors combined with antipsychotics, allow real‐time dose confirmation by sending ingesting events to wearable patches and smartphone apps [8, 9]. Wearable technologies such as smartwatches and skin patches can monitor physiological and behavioral indicators of drug adherence, including heart rate variability, sleep patterns, and activity, and spot abnormalities that may suggest missed doses or an impending relapse [10]. Meanwhile, pharmacogenetic profiling, such as CYP2D6 genotyping, and biomarker assays which include point‐of‐care metabolite detection in blood, saliva, or urine, provide biochemical confirmation of drug exposure and individual metabolic capacity, allowing for objective cross‐validation of digital signals and personalized dosing plans [11]. These convergent technologies promise to transform the paradigm from sporadic, subjective adherence checks to integrated, multimodal monitoring platforms that enable early detection of nonadherence, provide individualized feedback, and adaptive therapy. This review critically examines the state‐of‐the‐art innovations in monitoring treatment adherence, identifies existing challenges, and proposes future ways to drive positive treatment outcomes among patients with schizophrenia. Materials and Methods A narrative review was thoroughly conducted to obtain information relevant to the aim of the study. With a focus on innovative ways of managing schizophrenia, each author independently retrieved peer‐reviewed articles from electronic databases namely PubMed, Google Scholar, ScienceDirect, and Web of Science. The search strategy involved the use of key terms such as “adherence,” “antipsychotics,” “digital pills,” “wearable devices,” “psychiatry,” “personalized medicine,” and “pharmacology.” These terms were combined using Boolean operators: “AND” and “OR” to form suitable search strings. The inclusion criteria consisted of studies that reported on patients' adherence and use of digital tools/biomarkers in managing schizophrenia. Furthermore, only studies written in the English language and published up to 2026 were included to ensure a review and analysis of the most recent information. For exclusion criteria, studies focusing on the digital innovations and biomarkers in management of neurological conditions other than schizophrenia were excluded. Thereafter, all relevant articles were snowballed and aggregated in Zotero software to ensure consideration of adequate information in this review. Upon checking all articles, no duplicates were detected. Finally, all collated articles were cross‐checked to ensure their relevance to the aim of the review, culminating in a narrative synthesis of 76 papers in the final report. Challenge of Treatment Adherence in Schizophrenia While treatment adherence is essential for individuals with schizophrenia, it remains a major challenge. Several recent studies suggest that 50% nonadherence among patients with schizophrenia could trigger relapse, hospitalization, and impairment of their quality of life [12, 13]. Conventional methods of assessing adherence include self‐reports, pill counts, and reviewing pharmacy refill records. However, these methods have limitations including recall bias from self‐reports and failure to confirm actual ingestion when using pill counts, plus the pharmacy records may be fulfilled but do not support the claim that the medication was ingested as directed [12]. Adhering to prescribed plans is the key to treatment efficacy, not only in terms of healthcare expenditure but also in achieving good patient outcomes. Poor adherence can increase financial burdens, particularly due to prolonged hospitalization as a result of relapses. In the United States of America alone, this is estimated to add approximately $1.5 billion annually [14]. Moreover, poor compliance impacts patients considerably, leading to a heightened need for emergency psychiatric services and worsening of symptoms [15]. This undermines the benefits that medications are supposed to provide and lowers overall quality of life. Among the many reasons for nonadherence include cognitive deficits related to schizophrenia, causing patients to forget to take their medications. Additionally, the side effects of antipsychotic agents, for example, weight gain or sedation may discourage a patient from continuing treatment [5]. The other critical factor is the socioeconomic one, which includes limited access to health care facilities, which heightens the risk of treatment nonadherence due to instability in housing or lack of social support [16] (see Figure 1). Factors contributing to nonadherence in schizophrenia treatment. Digital Innovations in Monitoring Adherence to Treatment Digital Pills The main challenge in managing schizophrenia is ensuring adherence to medication regimens, as nonadherence is a leading cause of relapse and hospitalization [17]. Digital pills are used to ensure treatment adherence, particularly for chronic conditions like schizophrenia. These systems consist of an ingestible sensor embedded within a pill, a wearable patch usually worn on the torso, and a mobile or cloud‐based application that collects and analyzes the data [18]. Once ingested, the sensor is activated by the acid in the stomach and sends a signal to the wearable patch, which records the date and time of each digital pill ingestion and transmits data to a connected device such as a smartphone or tablet via Bluetooth for monitoring by healthcare practitioners [18, 19]. The patch also records additional physiological data such as heart rate, body position, and activity levels [20]. The FDA‐approved Abilify MyCite system, which is used in individuals with schizophrenia, is among the most well‐known examples. Aripiprazole is a second‐generation antipsychotic that has been approved for the treatment of schizophrenia in adults. This digital pill combines aripiprazole with a sensor that is made of copper, magnesium, and silicon and is developed by Proteus Digital Health [18, 21]. Clinical trials show that these systems can accurately confirm medication ingestion events, with adherence detection rates reaching above 95% [9]. These digital pills enable objective tracking, which is an improvement from the traditional self‐reporting or pill counts, which are often unreliable in psychiatric populations. Digital systems can send out alarms or reminders when dosages are missed and they provide real‐time feedback [7]. Therefore, digital pills can help differentiate between true nonadherence and pharmacological resistance, which is important for managing schizophrenia [22]. Digital pills provide data related to ingestion that can be directly correlated with pharmacokinetic parameters such as plasma drug concentration and time to steady state. For example, aripiprazole has a long half‐life of approximately 75 h, and consistent intake is required to maintain stable therapeutic plasma concentrations [23]. Therefore, digital pill ingestion timestamps allow clinicians to accurately interpret the measured plasma levels and help identify whether subtherapeutic concentrations are due to nonadherence, altered metabolism, or pharmacokinetic variability [24]. In addition, antipsychotic efficacy depends on adequate dopamine, D2, receptor occupancy, usually 60%–80%, while higher occupancy increases the risk of adverse effects such as extrapyramidal symptoms (acute dystonia, akathisia, pseudoparkinsonism, and tardive dyskinesia) [25]. By leveraging the dosing history, clinicians are able to optimize dosing, prevent toxicity, and differentiate pharmacological resistance from nonadherence. However, challenges such as cost, privacy concerns, and patient acceptance limit widespread adoption of the digital pills [26] (see Figure 2). Working mechanism of digital pill technology. Wearable Devices Traditional monitoring methods, such as in‐person consultations, do not capture real‐time fluctuations in symptoms and provide a less comprehensive view of a patient's day‐to‐day experience [27]. Wearable technology is an innovative approach to monitoring treatment adherence in schizophrenia. This technology provides real‐time data to improve both treatment adherence and clinical outcomes. Devices such as smartwatches, biosensor patches, and fitness bands can collect real‐time behavioral and physiological data such as sleep patterns, heart rate variability (HRV), physical activity, and even finger taps that reflect adherence or emerging relapse [28]. Furthermore, the wearable devices use built‐in sensors such as accelerometers, gyroscopes, optical heart rate monitors, skin temperature sensors, and electrodermal activity sensors to collect real‐time physiological and behavioral data [29]. These metrics provide information about the patient's routine, emotional state, stress levels, and physical health, which are critical in understanding treatment response and adherence. Wearables continuously collect passive data, hence minimizing patient burden. For example, a decrease in activity or increased sleep irregularities may signal medication nonadherence or symptom exacerbation [30]. Furthermore, wearables are excellent in integration with patient management systems. Through Bluetooth or Wi‐Fi, data from the wearable syncs with mobile applications, electronic health records (EHRs), or cloud‐based platforms [31]. In addition, wearable devices are usually integrated into EHR systems or mobile health apps; hence, such devices can generate automated alerts for care teams, supporting timely interventions [32]. Furthermore, wearables provide better patient engagement through self‐tracking and enhanced personalization of care [33]. The monitoring process can involve family members and caregivers, ensuring that individuals receive the necessary support in real‐time. Wearable devices provide objective pharmacodynamic parameters that determine therapeutic effects and adverse drug reactions of antipsychotic medications. Antipsychotics exert their therapeutic effects through dopamine D2 receptor antagonism or partial agonism, which affects motor pathways, autonomic function, and sleep regulation [34]. Parameters such as reduced physical activity may indicate excessive dopamine blockade leading to extrapyramidal symptoms such as bradykinesia or rigidity. In contrast, restlessness and increased activity may indicate akathisia [35]. Furthermore, changes in heart rate variability show autonomic nervous system effects, such as potential cardiotoxic effects such as QT interval prolongation [36]. Additionally, increased sleep duration and sedation may show antihistaminergic and anticholinergic effects of certain antipsychotics [37]. Through correlation of this data regarding dosing information, clinicians can assess pharmacodynamic response, detect early adverse drug reactions, and optimize dosing to improve efficacy while minimizing toxicity (see Table 1). TABLE 1Comparative analysis of popular wearable devices used in monitoring adherence in schizophrenia treatment.DeviceFeatures trackedStrengthsLimitationsReferencesFitbit ChargeSleep, physical activity, and finger tapsLong battery life, user‐friendly appLimited psychiatric‐specific metrics[28, 30, 38]Apple Watch SeriesActivity, HRV, ECGEnhanced user interface, health integrationExpensive, needs frequent charging[39, 40]Empatica E4Electrodermal activity, skin temperature, HRReal‐time dataHigh cost, limited commercial access[41, 42]BioPatch by ZephyrECG, respiration, postureClinical validation (FDA approval), accurate HRV measurementElectrodes and skin irritation[43, 44] Comparative analysis of popular wearable devices used in monitoring adherence in schizophrenia treatment. Biomarker‐Based Monitoring Role of Biomarkers in Adherence Although their roles differ, neurochemical biomarkers are useful markers for monitoring adherence to antipsychotic medication. Some biomarkers provide indirect information by reflecting biological responses to treatment or changes in disease status, whereas others directly verify recent medication exposure. The latter provide information which is more specific to monitoring adherence. Dopamine metabolites such as homovanillic acid (HVA), found in blood and cerebrospinal fluid (CSF) of people with schizophrenia, fluctuate regularly with antipsychotic treatment. Conducted experiments have demonstrated that plasma or CSF HVA levels not only predict response to antipsychotic drugs but can also provide indirect information on medication‐taking behavior [45]. Similarly, inflammatory markers react in a typical manner to antipsychotic treatment. The levels of interleukins IL‐1β, IL‐6, and TGF‐β decrease following antipsychotic therapy and primarily indicate treatment response and disease status. This reflection provides supportive information that may complement assessment of adherence. Other inflammatory markers, including IL‐12, IFN‐γ, TNF‐α, and soluble IL‐2 receptor, show consistent correlations with treatment resistance and severe psychopathological symptoms, while levels of IL‐12 are associated with neurocognitive deficits and poor functional outcomes [45, 46]. Collectively, these markers provide valuable information on treatment response, disease progression, and treatment resistance, which can assist in distinguishing between adherent and nonadherent patients when interpreted along with other clinical measures [47]. Genetic and cellular markers similarly reflect biological response to antipsychotic treatment which can help in monitoring adherence. The expressions of dopamine receptors (DRD2, DRD3, and DRD4) in peripheral lymphocytes change quantitatively according to treatment status [48]. Research has demonstrated that lymphocyte DRD2 binding is decreased following treatment with antipsychotic medications such as loxapine [45]. Besides, peripheral blood mononuclear cells show reduced pro‐inflammatory cytokine expression and increased anti‐inflammatory markers during effective antipsychotic treatment [48]. Serum brain‐derived neurotrophic factor (BDNF) levels correlate with central nervous system BDNF levels and increase following antipsychotic treatment. This change corresponds with cognitive and symptomatic improvements, potentially serving as markers of treatment response [49]. While these markers indicate treatment status, they could prompt clinicians to assess whether treatment outcomes are due to adherence or other medical reasons. In contrast, pharmacokinetic biomarkers provide direct and objective evidence of recent ingestion of medications. Thus, they have greater value in monitoring adherence. Drug metabolites such as norclozapine and 9‐OH‐risperidone in urine, olanzapine and quetiapine in saliva, and haloperidol in blood provide objective, real‐time verification of recent antipsychotic drug intake [50]. Technological advancements have further enhanced the detection of these biomarkers, enabling point‐of‐care devices to detect drug metabolites from blood, saliva, or urine with good sensitivity [51]. New technologies, such as aptamer‐based graphene field effect transistor (AptG‐FET) technology, integrate highly specific aptamers with electrically responsive graphene channels. This technology enables detection of antipsychotic drug metabolites such as norclozapine and 9‐OH‐risperidone in urine, olanzapine and quetiapine in saliva, and haloperidol and risperidone in blood, through the transduction of aptamer‐target binding into electrical signals [52]. By directly measuring drug metabolites, these platforms provide ultrasensitive, real‐time, noninvasive monitoring of recent ingestion of medication, thus overcoming limitations of self‐reporting and facilitating personalized treatment intervention in schizophrenia [52]. Biomarker‐based monitoring, particularly through direct measure of medication ingestion, reduces the risk of misclassifying nonadherence and consequently minimizes the likelihood of unsuitable treatment switch [53]. In the event of adherence problems, these approaches may also facilitate earlier intervention, thereby possibly reducing relapse and hospitalization. Furthermore, integrating biomarker data with clinical decision‐making supports more individualized treatment for schizophrenia, thus enhancing the therapeutic relationship between healthcare professionals and patients [51] (see Figure 3). Biomarker‐based monitoring process: from biomarker detection to adherence monitoring. Biomarkers detection and analysis (as shown in Figure 3) are used to extend bedside assessment by including therapeutic drug monitoring for antipsychotic medications through measurement of drug or metabolite concentrations. These pharmacokinetic biomarkers are translated into a clinically useful measure of the patient's drug exposure level by comparing measured concentrations with established dose‐related reference ranges [54]. This enables clinicians to differentiate between subtherapeutic exposure due to poor adherence or metabolic alterations from adequate drug exposure despite persistent symptoms [55]. When biomarkers indicate subtherapeutic drug exposure, adherence‐focused intervention (e.g., educational or behavioral) or pharmacokinetic adjustments (e.g., dose escalation, address drug–drug interaction, switch to a long acting injection) can be initiated [54]. Conversely, when adequate drug exposure is confirmed despite persistence of symptoms, clinicians are prompted to explore alternative factors contributing to the patient's current clinical condition, including the potential need to reconsider the patient's pharmacological regimen (i.e., molecule switching or augmentation). Integration of Digital and Biomarker Data The integration of digital tracking tools with biomarker detection is a powerful approach to comprehensively monitor medication adherence in schizophrenia treatment [53]. The combination creates a detailed monitoring system that tracks both patients' behavior using digital phenotyping and physiological signs through biomarker confirmation as discussed in the previous sections. In addition to digital pills, methods such as urine LC–MS/MS used in monitoring of medication compliance can provide objective confirmation of drug ingestion in patients receiving antipsychotic drugs. This is supported by a study by Kim et al. [56] in which urine LC–MS/MS demonstrated high sensitivity to 53 psychotropic substances, with limits of detection ranging from 0.07 to 1.5 ng/mL. Furthermore, graphene‐based saliva biosensors support continuous wearable monitoring platforms by offering noninvasive, real‐time biochemical monitoring with enhanced analytical sensitivity due to graphene's high electrical conductivity and large surface area‐to‐volume ratio [52]. Combining these approaches can enhance the accuracy of evaluating adherence, strengthen personalized care, and potentially reduce relapse risk among patients with schizophrenia. The integration of wearable and blood biomarker data enables clinicians to develop data‐driven approaches, supporting pharmacological decision‐making in patients with schizophrenia by creating practical, actionable clinical algorithms from theoretical frameworks [30]. For instance, a low activity signal that is generated by a wearable device along with low drug metabolites indicated by the biomarkers are a good indicator of medication nonadherence. In this case, the first response would be to take steps to improve the patient's adherence such as verifying the correct dose, implementing digital pill technologies (FDA approved ingestible sensor technologies), or converting the patient to an oral long‐acting formulation (OLAF) [30]. On the other hand, if drug metabolites are found to be within normal limits but the wearable device shows low activity, it may indicate either that the patient has progressed through the disease or the patient is experiencing a prodrome to a relapse (e.g., autonomic dysregulation or cognitive decline that can be detected by digital phenotyping of the wearable data) [57]. The appropriate response in these situations would be to implement dose optimization, dose augmentation (e.g., add clozapine if the patient meets TRS criteria), or to adjust their current antipsychotic regimen to prevent relapse based upon the findings from the wearable device and/or the patient's drug metabolites [58]. Potential Impact on Patient Outcomes Improving adherence to prescribed medications remains a significant challenge in healthcare, particularly for psychiatric patients. Suboptimal adherence results in negative health outcomes and increased healthcare costs [59, 60]. As a result, researchers studying medication adherence have adopted an interdisciplinary approach that integrates medicine, engineering, and social sciences to better understand and tackle the issue of nonadherence. A systematic review conducted by Addisu et al. [2] indicates that nonadherence with treatment regimen is driven by not only treatment‐related factors but also patient‐specific factors, including substance and alcohol use, perceived stigma, and a lack of family support. This highlights the multifactorial nature of nonadherence and the need for targeted interventions to improve patient outcomes. Technological and behavioral strategies have demonstrated improvements in medical adherence and reduction of relapse. Digital reminder systems improved adherence by up to 25% while personalized education increased adherence rates by 20% [61]. Additionally, social support interventions such as family interventions and family psychoeducation have shown robust benefits in reducing the risk of relapse among patients with schizophrenia [62]. These findings suggest that combining digital and behavioral strategies could be more effective than single‐component interventions. Digital and personalized approaches enable more engagement by providing customized recommendations that are based on patient behavior. Moreover, real‐time alerts reinforce retention of information by serving as reminders at critical times [63, 64]. One way to provide this level of interaction is through digital pills that not only monitor the absorption of medications but also provide information on medication adherence [24]. Beyond these figures, the clinical implications are even broader. Hamine et al. [65] highlight that continuous digital monitoring leads to better medication timing and dosage accuracy, resulting in improved therapeutic outcomes for chronic illnesses. Direct digital engagement with patients serves two main purposes: it prevents lapses of memory and makes the patients more engaged and, thus, more responsible for their medication‐taking. A report on a study examining patients' preferences for technology‐based behavioral interventions indicates that 90% of patients were interested in a tech‐based intervention for their health [66]. These findings indicate the possibility of digital direct engagement to lead to better adherence results even though the approach is not yet perfect due to concerns including privacy and complexity of digital tools among others. Customized digital treatment inspects the psychological and behavioral roadblocks that keep patients from adhering to their treatment plans. It looks directly at individual patient data to see how that patient is behaving regarding their treatment. If a patient seems to be interacting with their digital tools as if they are ignoring their treatment, then the digital tools can take that data and inform the clinician about a nonadherent patient [67]. Another important aspect is the economic benefits. Martin et al. [68] reported that in a cohort of patients, the introduction of digital adherence tools resulted in a significant reduction in health system costs, about $1200 per patient annually. Moreover, a systematic review by Dilla et al. [69] found that in the management of schizophrenia, there was a significant decline in the mean overall cost from $11111.3 to $7883.8 per patient, mainly driven by reduction in hospitalization. Challenges and Ethical Considerations Digital and biomarker‐based monitoring tools in the management of schizophrenia have exciting possibilities in promoting treatment adherence. However, there are issues and ethical concerns that must be resolved to ensure equitable implementation. One of these issues relates to cost and accessibility. These tools can be costly, from the initial implementation to essential digital maintenance activities such as data protection measures, which are often overlooked in funding allocations [70]. Therefore, due to high costs, people in low‐resource environments may find it more difficult to obtain such advanced digital tools and biomarker technologies. In spite of the heavy cost, others might argue that they can be viewed as capital investment into the patient's long‐term health. A paper by Carrascal‐Laso et al. [71] highlights that using biomarker‐based systems like pharmacogenomics in psychotic conditions has the potential to reduce costs in the long term with a cost–benefit ratio of 3.31–3.59. This would mean, for every $1000 spent on a biomarker‐guided treatment, the healthcare system benefits by saving about $3500 in direct costs. Moreover, research shows that relapse is far more expensive than treating stable patients who have not relapsed [72]. Additionally, security and privacy can pose a severe threat to the handling of health data as it would raise issues regarding possible misuse. Therefore, it is important to ensure public trust and ethical practices in the development of strong data protection systems combined with informed consent during data collection [73]. Collection and storage of real‐time adherence habits and behavior information can increase vulnerability of the data, especially because it is for psychotic populations who are at a higher risk of stigma and discrimination for their diagnosis or link to treatment. Furthermore, as much as digital monitoring could facilitate patient compliance, these interventions may be seen as intrusive, affecting the patient–provider relationship as they would threaten autonomy. Thus, a balance must be found between technological merit and health care users being fully informed on the purpose and consequences, showing respect for the patient's ability to opt in to the service when they are comfortable with the idea [70]. Besides, a huge barrier lies in scalability and infrastructure challenges. For instance, the consensus study testing digital interventions for people with schizophrenia and severe mental illness found that consistent internet access and lack of sufficient digital literacy are a huge barrier to such digital interventions, which is necessary for successful widespread implementation [70]. Without improving healthcare infrastructure and digital literacy, such technology may deepen the gap it proposes to bridge. Thus, there should be substantial investment in the infrastructure, clinician training, and patient education for the full realization of the benefits of digital adherence tools in schizophrenia management (see Table 2). TABLE 2Challenges in implementing digital and biomarker‐based adherence solutions.ChallengeDescriptionFinancial barriersHigh costs limiting widespread coverageInfrastructure needsRequirement for technological infrastructure and trainingPrivacy concernsRisks associated with data breaches and unauthorized accessEthical considerationsEnsuring informed consent and respecting patient autonomy Challenges in implementing digital and biomarker‐based adherence solutions. Future Directions The future of adherence‐promoting technology is in leveraging artificial intelligence (AI) to identify individuals who are unlikely to follow their treatment plans. This will facilitate a data‐driven revolution in adherence science by applying advanced AI analytics to existing adherence statistics. Ultimately, it will help us discover more accurate patterns to spot people who are at risk of nonadherence. Predictive models can then alert healthcare providers before lapses occur, enabling proactive interventions that prevent relapses, hospitalization, and worsening disease states. For example, machine learning algorithms have already demonstrated the ability to forecast medication lapses in chronic diseases such as diabetes and hypertension, providing valuable opportunities for early engagement [74]. Future adherence strategies will revolve around the concept of personalization. By studying the unique attributes of each behavior, thought, and social surroundings, AI can now prescribe, with some degree of certainty, a path for better adherence to a given treatment plan. For instance, a patient with cognitive impairment may require a schedule of reminders tailored not only to the time of day but also to the between‐subject variability in when one might be most likely to respond to an auditory or visual cue [75]. Interventions are now being designed with the knowledge that not all brains are the same. An all‐encompassing care model that integrates digital technologies and biomarkers will boost adherence management even more. This model comprises real‐time, interwoven collaboration between patients, caregivers, and clinicians to ensure that adherence strategies are as comprehensive, nimble, and sustainable as possible. Further studies indicated that the integration of wearable devices, electronic health records (EHRs), and telehealth platforms will enable real‐time adherence monitoring, immediate feedback, and timely clinical support. Fortunately, wearables now come in a variety of forms. In addition to smartwatches and the forerunner to the modern wearable, the fitness band, other types of wearable sensors are continuously being developed [76]. Wearables and EHRs alone will not make for a complete adherence management system. Furthermore, combining digital adherence monitoring with behavioral counseling through telehealth sessions can enhance engagement, especially in remote or underserved areas. Future platforms may also incorporate virtual health coaches and AI‐driven chatbots to provide 24/7 personalized adherence support. Patel et al. [76] emphasized that a systems‐based approach addressing both technical and human aspects of medication adherence will likely achieve the most sustainable outcomes. Conclusion Digital and biomarker‐assisted technologies have simplified challenges in accurately assessing treatment adherence in schizophrenia. Wearables track physiological and behavioral indicators, such as heart rate variability, activity rhythms, and sleep patterns, which provide signals not only of medication ingestion but also of impending relapse risk, whereas sensors co‐formulated with antipsychotics confirm doses in real‐time. At the same time, point‐of‐care drug metabolite testing and pharmacogenetic profiling (e.g., CYP2D6 genotyping) offer both scientific evidence and dose individualization information. These approaches provide a system that is better than pill counting, self‐reporting, and pharmacy records. This system provides real‐time, accurate information that can be used to guide quick and individualized intervention. However, there are significant challenges that should be overcome before these aspirations are fully realized. The high cost of devices and infrastructure, the need for strong regulations to protect data privacy and security, and the importance of patient‐centered design and ongoing consensus processes to address ethical concerns, including informed consent challenges among vulnerable populations, need to be addressed. Codesigning with patients, caregivers, and clinicians is necessary to ensure long‐term acceptability and engagement with monitoring technology. Pharmacists, psychiatrists, bioengineers, data scientists, and lawmakers should collaborate to create safe, effective, affordable, and ethical monitoring technology systems. By integrating these technologies into holistic care models that involve patient education, shared decision‐making, and remote support, stakeholders can leverage objective adherence data to optimize therapy, reduce relapses, and improve positive long‐term treatment outcomes. Author Contributions All authors have approved the final manuscript for submission. Samuel Inshutiyimana: conceptualization, writing – original draft, writing – review and editing, project administration. All authors: writing the first draft and revision. Graphical abstract was drawn and analyzed by Michael Matiop Aleu. Figure 1 was drawn and analyzed by Naomi Bwalya. Figure 2 was drawn and analyzed by Kush Rajeshbhai Rana. Figure 3 was drawn and analyzed by Michael Matiop Aleu. Table 1 was created by Kush Rajeshbhai Rana. Table 2 was created by Naomi Bwalya. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during this study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during this study.